Dr. David Ripin leads efforts at CHAI to improve access to medicines and diagnostics for diseases like HIV, malaria, and tuberculosis, through sustainable market interventions. Under his leadership, CHAI has implemented agreements with pharmaceutical companies reducing prices of key drugs and diagnostics by up to 80 percent. Joining CHAI in 2007, Dr. Ripin initially led the Pharmaceutical Sciences team, which was focused on reducing the cost of key drugs through recommending formulation, manufacturing process, and sourcing improvements, as well as conducting the transfer of these processes to manufacturing partners. Before joining CHAI, he worked at Pfizer, Inc., contributing to drug commercialization and manufacturing. Dr. Ripin holds a Bachelor of Science in Chemistry and Asian Studies from Washington University in St. Louis and earned his Ph.D. in Chemistry from Harvard University.
This panel will feature a discussion on partnerships that are focused on advancing diagnostics in LMICs to guide use of appropriate antibiotics. Panelists will share updates on their programs from different perspectives such as a donor perspective, an implementor experience and from a product development partnership perspective. Learn about the newly launched partnership called AMRASI (Antimicrobial Access and Stewardship Initiative) from Elijah Kahn from USAID, an update from on the Nigeria field studies to understand the epidemiology of bacteremia syndromes in children from Dr. Obaro from the University of Alabama, Bringham and about new diagnostics products and programs from Kavi Ramjeet of FIND. The panel will be moderated by David Ripin, Chief Science Officer | Clinton Health Access Initiative.